Atai Beckley Inc.

NASDAQ:ATAI

Biotechnology

Healthcare
$7.35 -1.35%

-$0.06 today

Market cap
$2.72B
Beta
1.60
P/E (TTM)
-1.4
EPS (TTM)
-$2.93
52W Low $2.00High $6.75

Volume 0.00M

Average 5.68M

ATAI Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Atai Beckley Inc.NASDAQ: ATAI

Net Income · Q2 FY2026 · quarter ended Jun 2026

Net income grows, but more slowly than its trailing trend

Q2 FY2026 net income of $32.52M (cash outflow) rose 17.2% year over year, behind the +459.1% change in trailing-twelve-month net income. Sequentially, it rose 9.1% from the prior quarter. Over 3 fiscal years it compounded at +61.3% a year.

Context

  • Net income amounted to 16142.0% of revenue in FY2025, down 32575.2 pp from a year earlier.
  • Net income grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 9 analysts of -$154.46M (-76.6%) for the fiscal year ending Dec 2026, a slowdown from the +339.9% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
-$32.52M+9.1% QoQ
Last fiscal yearDec 2025
-$660.05M+339.9% YoY
LTMJun 2026
-$668.24M+459.1% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+17.2%-27.3%-44.5 pp
1 year+339.9%-76.6%-416.5 pp
3-year CAGR+61.3%-46.4%-107.6 pp
5-year CAGR-41.7%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(660.05M) USD
Year-over-year change
-339.9%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How ATAI compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +459.1% is the 2nd highest of 11, against a peer median of +12.6%.
  • Net income amounts to 14939.4% of revenue for ATAI, versus a peer median of 1672.9%.
ATAI Competitors
Net Income for ATAI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ATAIAtai Beckley Inc.LTM Jun 2026$668.24M USD+459.1%+61.3%14939.4%
RLAYRelay Therapeutics, Inc.LTM Jun 2026$286.04M USD-8.2%-1.6%2763.6%
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 2026$243.25M USD-26.6%+24.1%112.0%
SANASana Biotechnology, Inc.LTM Mar 2026$241.99M USD+16.0%-3.2%—
IMTXImmatics N.V.LTM Mar 2026€217.14M EUR+906.0%—582.2%
DNTHDianthus Therapeutics, Inc.LTM Jun 2026$192.25M USD+67.5%+78.6%10097.0%
AMLXAmylyx Pharmaceuticals, Inc.LTM Sep 2026$163.2M USD+9.3%-10.0%—
NKTRNektar TherapeuticsLTM Jun 2026$157.13M USD+28.5%-23.6%287.8%
ORICORIC Pharmaceuticals, Inc.LTM Mar 2026$135.21M USD+1.8%+13.3%—
INBXInhibrx Biosciences, Inc.LTM Mar 2026$130.19M USD-107.7%-1.2%10014.2%
ELVNEnliven Therapeutics, Inc.LTM Sep 2026$113.48M USD+16.7%+40.2%—
Peer median (excluding ATAI) —+12.6%-1.2%1672.9%

Competitors are the stored peer set for ATAI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(174.24M)(157.42M)(43.9M)(150.05M)(660.05M)
Depreciation & Amortization47K168K319K473K1.01M
Deferred Income Tax39.14M5.07M000
Stock-Based Compensation63.36M42.38M32.98M25.49M0
Change in Working Capital(7.6M)(3.34M)7.47M(9.2M)(6.48M)
Accounts Receivables00000
Inventory00000
Accounts Payables2.3M(3.03M)2.14M(1.87M)(1.7M)
Other Working Capital(9.9M)(301K)5.33M(7.33M)(4.78M)
Other Non-Cash Items16.06M8.67M(80.99M)50.85M562.84M
Operating Cash Flow(63.25M)(104.47M)(84.12M)(82.44M)(102.68M)
Capital Expenditures(1.13M)(1.02M)(590K)(95K)(901K)
Acquisitions (Net)(52.94M)0(443K)359K4.64M
Purchases of Investments(23.66M)(309.66M)(186.22M)(15M)(98.95M)
Sales of Investments(955K)226.83M139.47M82.01M9.05M
Other Investing Activities(2.6M)(3.25M)(5.84M)(8.1M)(13M)
Investing Cash Flow(81.28M)(86.85M)(53.3M)59.17M(109.13M)
Debt Repayment1.59M15M05M7.71M
Common Stock Issued409.88M00535K283.43M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities2.42M5.19M(8.36M)(161K)(21.66M)
Financing Cash Flow409.86M20.79M(8.36M)5.37M269.48M
Effect of Forex Changes(320K)(1.12M)189K362K116K
Net Change in Cash265.02M(171.65M)(145.58M)(17.53M)57.8M
Free Cash Flow(64.37M)(105.49M)(84.71M)(82.53M)(103.58M)

Atai Beckley Inc.

NASDAQ:ATAI

Intrinsic Alpha fair value

Locked

Current Price

$7.35

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.